Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2014

Electronic Supplementary Material (ESI) for *Organic & Biomolecular Chemistry*This journal is (c) The Royal Society of Chemistry 2015

Supplementary Information for

Direct construction of 2-alkylbenzo-1,3-azoles via C-H activation of alkanes for C-C and C-X (X = O, S) bond formation

Arvind K. Yadav and Lal Dhar S. Yadav*


Green Synthesis Lab, Department of Chemistry, University of Allahabad,
Allahabad-211002, India

E-mail: ldsyadav@hotmail.com

- **I. General Information**: All commercially available reagents were used without further purification unless otherwise specified by a reference. Solvent was purified by the usual methods and stored over molecular sieves. All reactions were performed using oven-dried glassware under a nitrogen atmosphere. Organic solutions were concentrated using a Buchi rotary evaporator. Column chromatography was carried out over silica gel (Merck 100–200 mesh) and TLC was performed using silica gel GF254 (Merck) plates. Melting point (m.p.) was determined by open glass tube. ¹H (400 MHz), ¹³C (100 MHz) NMR spectra were recorded on a Bruker AVII spectrometer in CDCl₃ using TMS as internal reference. All chemical shifts are reported in δ/ppm and coupling constants (*J*) in Hertz (Hz). MS (EI) spectra were recorded double focusing mass spectrometer.
- II. General procedure for the synthesis of 2-alkylbenzo-1,3-azoles: Charged a round bottom flask with aryl isothiocyanate/isocyanate 1 (1.0 mmol), alkane 2 (1.0 mL), DTBP (4.0 equiv.), Cu(OAc)₂ (10 mol%) and CH₃CN (3 mL). The contents were stirred at 120 °C under a nitrogen atmosphere for 6-12 h. After the completion of reaction (as indicated by TLC), it was quenched with water (10 mL) and extracted with ethyl acetate (3 × 10 mL). The organic phase was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to yield the crude product, which was purified by silica gel column chromatography using a mixture of EtOAc-Hexane (1:9) to give the pure product 3 in high yields (Table 2). The structure of the products was confirmed by comparison of ¹H, ¹³C NMR and MS spectral data with those reported in the literature. ¹


III. Copies of ¹H and ¹³C NMR spectra.

Compound 3a. ¹H NMR Spectrum (CDCl₃).




avtar saifpu@yahoo.co.in


Compound 3a. ¹³C NMR Spectrum (CDCl₃).




Compound 3b. ¹H NMR Spectrum (CDCl₃).




Compound 3b. ¹³C NMR Spectrum (CDCl₃).



Compound 3c. ¹H NMR Spectrum (CDCl₃).




Compound 3c. ¹³C NMR Spectrum (CDCl₃).




Compound 3d. ¹H NMR Spectrum (CDCl₃).


$$\begin{array}{|c|c|}\hline \\ S_{3d} \\ \hline \end{array}$$




Compound 3d. ¹³C NMR Spectrum (CDCl₃).



Compound 3e. ¹H NMR Spectrum (CDCl₃).




Compound 3e. ¹³C NMR Spectrum (CDCl₃).



avtar saifou#vahoo.

Compound 3f. ¹H NMR Spectrum (CDCl₃).


$$O_2N$$
 S S



Compound 3f. ¹³C NMR Spectrum (CDCl₃).

$$O_2N$$


$$3f$$



Compound 3g. ¹H NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR-1 IN CDCl3 TCGLS/ARD/NMR02/K02



Compound 3g. ¹³C NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR-11N CDCl3 TCGLS/ARD/NMR02/K02



Compound 3h. ¹H NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR- 2 IN CDCl3 TCGLS/ARD/NMR02/K02



Compound 3h. ¹³C NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR-2 IN CDCl3 TCGLS/ARD/NMR02/K02



Compound 3i. ¹H NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR- AIN CDC13 TCGLS/ARD/NMR02/K02



Compound 3i. ¹³C NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR-3 IN CDCl3 TCGLS/ARD/NMR02/K02



Compound 3j. ¹H NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR-GIN CDC13 TCGLS/ARD/NMR02/K02




Compound 3j. ¹³C NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise

BR-GIN CDCl3 TCGLS/ARD/NMR02/K02




Compound 3k. ¹H NMR Spectrum (CDCl₃).



Compound 3k. ¹³C NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR-BIN CDCl3 TCGLS/ARD/NMR02/K02



Compound 31. ¹H NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR-C IN CDCl3 TCGLS/ARD/NMR02/K02



Compound 31. ¹³C NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR-CIN CDCl3 TCGLS/ARD/NMR02/K02




Compound 3m. ¹H NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise

BR-E IN CDCl3 TCGLS/ARD/NMR02/K02




Compound 3m. ¹³C NMR Spectrum (CDCl₃).



Compound 3n. ¹H NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise

BR-F IN CDC13 TCGLS/ARD/NMR02/K02




SF 400.1600400 MHz F2 - Processing parame SF01400.1524711 MF ====== CHANNEL D1 1,000000000 sec DW 62.400 usec AQ 2.0447731 sec FIDRES 0.244532 Hz SWH8012820 Hz SOLVENT CDCB PULPROG 2230 PROBHD 5mm PABB INSTRUM spect Date_2014.08.2 ! F2 - Acquisition Param

Compound 3n. ¹³C NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR-GIN CDCl3 TCGLS/ARD/NMR02/K02



Compound 30. ¹H NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR-DIN CDCl3 TCGLS/ARD/NMR02/K02



Compound 30. ¹³C NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR-DIN CDCl3 TCGLS/ARD/NMR02/K02



Compound 3p. ¹H NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR-MIN CDCl3 TCGLS/ARD/NMR02/K02



GB 0 LB 030 Hz SSB 0 ME WOW SF 400.1500400 MHz SI 16384 F2 - Processing paramet SFO1400.1524711 MHz PL1 - 2.00 dB P1 12 25 usec NUC1 1H ====== CHANNEL: TD0 1 D1 1,00000000 sec TE300.0 K DE 6.50 used DW 62400 usec RG 128 AQ 2.0447731 sec FIDRES 0.244532 Hz SWH8012820 Hz DS 0 NS 8 SOLVENT CDCB TD 32768 PULPROG 2230 PROBHID 5mm PABBO INSTRUM spect Time 13.11 Date_2014.12.13 F2 - Acquisition Parame PROCNO 1 EXPNO 1


NAME BR-M

Compound 3p. ¹³C NMR Spectrum (CDCl₃).



BR-MIN CDCI3 TCGLS/ARD/NMR02/K02


=CHANNEL 11 =



Compound 3q. ¹H NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise


BR-0: IN CDCl3 TCGLS/ARD/NMR02/K02



Compound 3q. ¹³C NMR Spectrum (CDCl₃).

CHEMBIOTEK, A TCG Lifesciences Enterprise

BR-OIN CDCl3 TCGLS/ARD/NMR02/K02



IV. References:

- 1. W.-M. Zhao, X.-L. Chen, J.-W. Yuan, L.-B. Qu, L.-K. Duana and Y.-F. Zhao, *Chem. Commun.*, 2014, **50**, 2018.
- 2. P. Ren, I. Salihu, R. Scopelliti and X. L. Hu, Org. Lett. 2012, 14, 1748.
- 3. P. Y. Xin, H. Y. Niu, G. R. Qu, R. F. Ding and H. M. Guo, *Chem. Commun.*, 2012, 48, 6717.
- 4. T. Yao, K. Hirano, T. Satoh and M. Miura, Angew. Chem., Int. Ed., 2012, 51, 775.
- 5. R. Xia, H.-Y. Niu, G.-R. Qu and H.-M. Guo, Org. Lett., 2012, 14, 5546.
- 6. G. A. Molander, V. Colombel and V. A. Braz, Org. Lett., 2011, 13, 1852.